Hypo-attenuated leaflet thickening in surgically-implanted mitral bioprosthesis.

Area of Science:

• Cardiovascular Medicine
• Biomedical Engineering
• Radiology

Background:

• Hypo-attenuated leaflet thickening (HALT) is documented in bioprosthetic aortic valves but remains uncharacterized in bioprosthetic mitral valves (bMV).
• Understanding bMV HALT is crucial for assessing its prevalence, hemodynamic impact, and relationship with anticoagulation therapy.

Purpose of the Study:

• To determine the prevalence of HALT in bioprosthetic mitral valves (bMV).
• To characterize the hemodynamic profile and clinical significance of bMV HALT.
• To investigate the role of anticoagulation therapy in bMV HALT.

Main Methods:

• A single-center cross-sectional study included 53 patients undergoing mitral valve replacement (MVR) with bMV.
• Cardiac-gated contrasted CT scans were used to assess leaflet thickening.
• Anticoagulant/antiplatelet use, patient characteristics, and echocardiographic hemodynamics were analyzed.

Main Results:

• HALT was identified in 5.7% (3/53) of patients with bMV.
• All affected patients were asymptomatic with trivial or mild mitral regurgitation.
• One patient with HALT was on therapeutic warfarin, questioning a purely thrombotic etiology.

Conclusions:

• The prevalence of HALT in bMV is low (5.7%) and appears asymptomatic.
• The presence of HALT in a patient on therapeutic anticoagulation suggests that thrombosis may not be the sole cause.
• Further research is needed to elucidate the pathophysiology and optimal management of bMV HALT.